Monthly Archives: November 2026

Credit Insurance and Receivables Protection for Peptide Exporters (2026)

For most peptide exporters the largest uninsured asset on the balance sheet is the money owed by overseas buyers. This guide explains what credit insurance actually covers, how limits are set, and where the policy stops and internal collection discipline has to take over. Key Research Points Receivables are the least insured asset in most […]

Destination-Country Registration and Import Permit Requirements for Peptides (2026)

The same vial can clear one border in a week and sit in another for a month, and the difference is usually a document the seller did not know was required. This guide covers how to map destination requirements before the order is accepted, who has to hold the permission, and how to keep the […]

Regulatory Inquiry Response and Commitment Tracking for Peptides (2026)

A regulatory inquiry arrives with a deadline and no room for a second version, and the commitments made in the reply outlive the question that prompted it. This guide covers triage, drafting, the discipline of promising only what can be delivered, and how to track commitments to closure. Key Research Points An inquiry is a […]

GMP Inspection Readiness and Backroom Conduct for Peptides (2026)

An inspection is a test of whether the quality system runs the way it is described, conducted in a room where the site has one chance to explain itself. This guide covers how readiness is built rather than staged, how the front and back rooms divide the work, and how to answer questions without creating […]

Sample Fees and Tooling Cost Allocation for Peptide Orders (2026)

Sample and tooling costs are small relative to the order they precede and large relative to the argument they cause. This guide explains how those costs are usually structured, where they hide, who owns what is paid for, and how to document the allocation so it does not resurface at the invoice stage. Key Research […]